FIELD: medicine; cardiology.
SUBSTANCE: treatment of severe cardiac insufficiency is ensured with offered 5-hydroxy-7-chlorine-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzasepine or its pharmaceutically acceptable salt for production of medical product and pharmaceutical composition, as well as with method of treatment. Method includes introduction of active substance in daily dose 0.1 mg/kg to less than 0.6 mg/kg.
EFFECT: effective treatment of cardiac insufficiency due to reduced liquid holdup in organism and normalised sodium concentration in blood serum with minimal by-effects.
16 cl, 7 tbl, 3 ex
